What is NCEL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NCEL?

P/E (TTM) is n/a and 52-week range is $1.83 to $17.25 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NCEL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NCEL?

The company profile lists net income (TTM) near -$7M, EPS (TTM) near -$1.33 when available from the market-data feed. Figures are informational and may lag live markets.

Where is NewcelX AG based, and what identifiers does Chartloom list?

The company context section lists headquarters in Zurich, Zuerich, CH, 5.4M shares outstanding, ISIN CH1442297896 when available from company profile and filing metadata.

NewcelX AG

$NCEL

Health Care · Biotechnology

IR Run Scenarios

Browse other companiesFree AI scores and summaries for more stocks

NewcelX AG

$NCEL

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The firm offers products like Quilience, which is a clinical-stage pharmaceutical compound. The company aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The firm also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The firm is a publicly traded company, listing on the NASDAQ.

Employees

1

Website

nlspharma.com/

IPO

2021-01-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

CH1442297896

Headquarters

Zurich, Zuerich, CH

Shares outstanding

5.4M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

1.35%

Browse other companiesFree AI scores and summaries for more stocks

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The firm offers products like Quilience, which is a clinical-stage pharmaceutical compound. The company aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The firm also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The firm is a publicly traded company, listing on the NASDAQ.

Employees

1

Website

nlspharma.com/

IPO

2021-01-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)